Delcath SystemsDCTH
DCTH
About: Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Employees: 76
0
Funds holding %
of 6,812 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
740% more call options, than puts
Call options by funds: $3.28M | Put options by funds: $390K
267% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 6
31% more funds holding
Funds holding: 52 [Q2] → 68 (+16) [Q3]
9% more capital invested
Capital invested by funds: $81.7M [Q2] → $89.3M (+$7.56M) [Q3]
7% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 15
0% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]
1.49% less ownership
Funds ownership: 38.12% [Q2] → 36.63% (-1.49%) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$21
79%
upside
Avg. target
$22
84%
upside
High target
$22
88%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 52 / 173 met price target | 88%upside $22 | Buy Reiterated | 11 Nov 2024 |
Canaccord Genuity John Newman 56% 1-year accuracy 15 / 27 met price target | 79%upside $21 | Buy Maintained | 18 Oct 2024 |
Financial journalist opinion
Neutral
Business Wire
4 hours ago
Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the exercise of 1.7 million Series E and E1 warrants which resulted in $16.3 million of funding. Approximately 6.6% of the warrants exercised were subject to cashless exercise provisions. The warrants, issued in July and August 2019 as a component of a private placement, h.
Neutral
Business Wire
4 weeks ago
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U.S. Food and Drug Administration (FDA) has completed its 30-day review of the Company's Investigational New Drug (IND) application for a Phase 2 clinical trial evaluating HEPZATO™ in combination with standard of care (SOC) for liver-dominant metastatic colorectal cancer (mCRC). With the FDA's revie.
Positive
Seeking Alpha
1 month ago
Delcath Begins Platform Expansion With Two Phase 2 Trials
Delcath's Q3 US sales hit $10 million. This unlocked $25 million in cash from its Tranche B Warrants, which will fund its Phase 2 trials for mCRC and mBC. HEPZATO KIT's hospital rollout is progressing well. Delcath plans to end the year with 15 centers and end 2025 with 30. Treatment has gone well at UCLA. Three retrospective clinical trials and the FOCUS trial's subgroup analysis add to the growing body of evidence which shows PHP's effectiveness in treating mUM and other tumor types.
Positive
Seeking Alpha
1 month ago
Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth
Delcath Systems' Q3 earnings revealed strong growth with $11.2M in revenue, driven by HEPZATO and CHEMOSAT sales, and an 85% gross margin. The company is expanding its commercial footprint with 12 active treatment centers and plans to reach 30 by the end of 2025. Promising growth drivers include new cancer indications for HEPZATO, potential label expansion, and combining with immune checkpoint inhibitors.
Neutral
Seeking Alpha
1 month ago
Delcath Systems Inc (DCTH) Q3 2024 Earnings Call Transcript
Delcath Systems Inc (NASDAQ:DCTH ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard Michel - CEO Sandra Pennell - SVP, Finance Kevin Muir - General Manager, Interventional Oncology Vojislav Vukovic - Chief Medical Officer Conference Call Participants Sudan Loganathan - Stephens Swayampakula Ramakanth - H.C. Wainwright John Newman - Canaccord Genuity Corp Yale Jen - Laidlaw & Company Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings and welcome to the Delcath Systems' Third Quarter 2024 Earnings Call.
Negative
Zacks Investment Research
1 month ago
Delcath Systems, Inc. (DCTH) Reports Q3 Loss
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.61 per share a year ago.
Neutral
Business Wire
1 month ago
Delcath Systems Reports Third Quarter 2024 Results and Business Highlights
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the third quarter ended September 30, 2024. Third Quarter and Recent Business Highlights Total third quarter revenues of $11.2 million, up 44% from the prior quarter, including $10.0 million from HEPZATO KIT™ (melphalan/Hepatic.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Believe Delcath Systems (DCTH) Could Rally 96.84%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 96.8% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
Zacks Investment Research
1 month ago
Delcath Systems (DCTH) Is a Great Choice for 'Trend' Investors, Here's Why
Delcath Systems (DCTH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Neutral
Business Wire
1 month ago
Delcath Systems to Participate in Upcoming Investor Conferences
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following upcoming investor conferences: Stephens Biotechnology Virtual Fireside Chats Date: Wednesday, November 13, 2024 Fireside Chat Time: 9:30 am Eastern Time Location: Virtual 15th Annual Craig-Hallum Alpha Select Conference Date: Tuesday, November 19, 2024 1.
Charts implemented using Lightweight Charts™